DeCure for Urethra adenocarcinoma

Primary urethral adenocarcinoma is an extremely rare malignancy, with an annual incidence in women of less than ten per one million, and adenocarcinomas accounting for roughly 10% of female urethral carcinomas, of which 40% are the clear cell variant. The evidence base consists almost entirely of case reports and small series, with no consensus on management. For early distal tumours, one 1997 review reports 5-year survival of 70–80% with surgery and 75% with brachytherapy alone. For proximal or entire urethral cancers, the same review advocates external beam radiotherapy combined with brachytherapy, with or without chemotherapy, to preserve the organ, reserving surgery for persistent or recurrent disease. A 2010 report describes two female patients with primary urethral adenocarcinoma treated with concomitant chemotherapy and external beam radiotherapy followed by interstitial brachytherapy, but provides no survival or response data.

A 2015 case report describes a 36-year-old man with primary clear cell adenocarcinoma of the male urethra who refused surgery and received cystoscopic-assisted intraluminal high-dose-rate brachytherapy, 36 Gy in 9 fractions followed by a boost of 24 Gy in 6 fractions. At 11 months post-treatment the disease was well controlled with no reported toxicity. A 2021 case report of a different 36-year-old man with the same diagnosis describes local and systemic recurrence about 30 months after surgery for localised disease; he was then treated with platinum-based chemotherapy and achieved an excellent clinical and radiological response, though no duration of response is given. A 2020 case report describes a 40-year-old woman with metastatic clear cell adenocarcinoma of the urethra who, after genetic testing, received non-platinum-based chemotherapy with paclitaxel and bevacizumab. She achieved a complete response by PET scan after 6 cycles, but after 11 cycles a subsequent PET scan confirmed progression of metastatic disease. She was then given two cycles of doxorubicin, which produced only a mixed response.

The remaining reports add little quantitative information. A 2016 case report notes that urethral adenocarcinoma predominantly affects women over 50, rarely presents with distant metastasis, but that mutilating surgery and permanent urinary catheter use can severely impair quality of life. A 2022 report states that incidence increases with age, peaking in women over 65, and that the tumour carries a relatively poor prognosis. A 2005 Spanish-language review of two cases concludes that distal urethral carcinoma is more amenable to treatment and has a better prognosis than proximal or entire urethral carcinoma, which is often associated with extensive local invasion and metastasis. No abstract reports a randomised trial, a prospective cohort, or any comparative efficacy data.

What is missing is fundamental: there are no prospective trials, no standardised staging or treatment protocols, and no molecular characterisation beyond a single case of personalised chemotherapy. The numbers that exist come from a 1997 review of mixed histologies and are decades old. Patient stratification by tumour site, histology, and mutation status is absent. Funding for multi-centre registries or cooperative trials in this disease is effectively non-existent, and without such infrastructure, no reliable estimate of optimal therapy, sequencing, or long-term outcomes can be produced.